Olmesartan/Amlodipin/Hct Viatris (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipin/Hct Viatris, is an angiotensin II receptor blocker presented as a tablet for oral use. It helps lower blood pressure in adults with hypertension. GNH USA supplies Olmesartan/Amlodipin/Hct Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality for cardiovascular therapy.

Olmesartan/Amlodipin/HCT is indicated for the management of hypertension, acting on the renin‑angiotensin system, calcium channels, and diuretic pathways.

Essential hypertension: provides greater blood pressure reduction than monotherapy. Secondary hypertension: assists in controlling blood pressure when multiple mechanisms are involved. Hypertension with edema: amlodipine mitigates vascular tone while olmesartan reduces angiotensin‑II effects, improving overall control.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Peripheral edema, especially of the lower limbs. - Flushing or warmth sensation. - Fatigue or mild weakness. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Severe hypotension leading to fainting. - Acute renal impairment or sudden rise in serum creatinine. - Electrolyte disturbances such as hyponatremia or hypokalemia. - Hepatic dysfunction with elevated transaminases. - Pancreatitis presenting with abdominal pain and vomiting.

Before initiating therapy, clinicians should consider several safety aspects.

Monitor renal function: assess serum creatinine and eGFR at baseline and periodically. Assess electrolytes: watch for hyponatremia, hypokalemia, or hyperkalemia due to the thiazide component. Avoid in severe hepatic impairment: dose adjustment may be required. Use caution in aortic stenosis: risk of marked hypotension. Pregnancy: contraindicated in the second and third trimesters because of fetal toxicity. Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original packaging.

Olmesartan/Amlodipin/HCT may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: potential hyperkalemia. - Lithium: elevated lithium concentrations and toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors: additive risk of hyperkalemia and renal dysfunction. - NSAIDs: may blunt antihypertensive effect and affect renal function. - Other antihypertensives: risk of additive hypotension; monitor blood pressure closely.